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Background: The current vaccines failed to provide substantial protection against porcine reproductive and
respiratory syndrome (PRRS) and the new vaccine development faces great challenges. Sialoadhesin (Sn) and CD163
are the two key receptors for PRRS virus (PRRSV) infection of porcine alveolar macrophages (PAMs), but the artificial
microRNA (amiRNA) strategy targeting two viral receptors has not been described.
Methods: The candidate miRNAs targeting Sn or CD163 receptor were predicted using a web-based miRNA design
tool and validated by transfection of cells with each amiRNA expression vector plus the reporter vector. The
amiRNA-expressing recombinant adenoviruses (rAds) were generated using AdEasy Adenoviral Vector System. The
rAd transduction efficiencies for pig cells were measured by flow cytometry and fluorescent microscopy. The
expression and exosome-mediated secretion of amiRNAs were detected by RT-PCR. The knock-down of Sn or CD163
receptor by rAd- and/or exosome-delivered amiRNA was detected by quantitative RT-PCR and flow cytometry.
The additive anti-PRRSV effect between the two amiRNAs was detected by quantitative RT-PCR and viral titration.
Results: All 18 amiRNAs validated were effective against Sn or CD163 receptor mRNA expression. Two rAds expressing
Sn- or CD163-targeted amiRNA were generated for further study. The maximal rAd transduction efficiency was 62% for
PAMs at MOI 800 or 100% for PK-15 cells at MOI 100. The sequence-specific amiRNAs were expressed efficiently in and
secreted from the rAd-transduced cells via exosomes. The expression of Sn and CD163 receptors was inhibited
significantly by rAd transduction and/or amiRNA-containing exosome treatment at mRNA and protein levels. Both
PRRSV ORF7 copy number and viral titer were reduced significantly by transduction of PAMs with the two rAds and/or
by treatment with the two amiRNA-containing exosomes. The additive anti-PRRSV effect between the two amiRNAs
was relatively long-lasting (96 h) and effective against three different viral strains.
Conclusion: These results suggested that Sn- and CD163-targeted amiRNAs had an additive anti-PRRSV effect against
different viral strains. Our findings provide new evidence supporting the hypothesis that exosomes can also serve as an
efficient small RNA transfer vehicle for pig cells.
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Porcine reproductive and respiratory syndrome (PRRS)
is an economically important swine disease characterized
by reproductive failures in sows and respiratory syn-
dromes in pigs of all ages [1]. Since its first outbreak in
the United States and Canada in 1987, the disease has
been causing heavy economic losses to the pig industry
worldwide [2,3]. Although both inactivated and live-
attenuated vaccines are available for PRRS control, these
vaccines failed to provide sustainable protection against
the disease, against heterogeneous viral strains in par-
ticular [4]. Porcine reproductive and respiratory syn-
drome virus (PRRSV) is an enveloped positive ? sense
RNA virus classified within the Arteriviridae family [5,6].
In pigs, the virus targets the cells of monocyte/macro-
phage lineage [7,8], causing severe cell death, slow and
weak antiviral responses, and/or persistent infections. In
addition, PRRSV uses additional evasion strategies to
escape the host innate and acquired immunity, including
interference with antigen presentation, antibody-mediated
infection enhancement, reduced cell surface expression of
the viral proteins and shielding of the neutralizing epi-
topes. As a consequence, new PRRS vaccine development
faces great challenges since they suffer from the immune
evasion strategies of the virus and the highly antigenic het-
erogeneity of field viral strains [4].
PRRSV enters the target cells by receptor-mediated
endocytosis [9]. To date, at least three PRRSV receptors
have been identified on porcine alveolar macrophages
(PAMs), including heparan sulphate as the general at-
tachment factor, sialoadhesin (Sn or CD169) for the viral
binding and internalization, and CD163 for the viral
genome release [10]. Previous studies have shown that
PRRSV infection of PAMs can be blocked partially by
the Sn- or CD163-specific antibody or completely by a
combination of two antibodies [11], and that adenoviral
(Ad) vector-delivered soluble Sn and CD163 receptors
have an additive effect against PRRSV infection [12].
These data suggest that the two viral receptors are the
useful targets for designing new strategies for PRRS
control.
RNA interference (RNAi) is a post-transcriptional gene
silencing mechanism conserved in eukaryotes ranging
from worms to humans [13]. Since its discovery in 1994
as an innate antiviral mechanism, RNAi has become a
feasible strategy against a variety of viral infections [14].
Two types of small RNAs, namely small interfering
RNAs (siRNAs) and microRNAs (miRNAs), are the cen-
tral players in RNAi process, both of which inhibit gene
expression by binding to the target RNA molecules [15].
A recent study has shown that viral vector-expressed
artificial miRNAs (amiRNAs) are more effective than
the conventional short hairpin RNA (shRNA) strategy
[16,17]. Among the viral vectors available, Ads havebeen used extensively as the gene transfer vectors for
gene therapy and vaccine development with several ad-
vantages, including efficient gene delivery, transduction
of both dividing and non-dividing cells, ease of propaga-
tion to high titers, and minimal risk of genomic inser-
tional mutagenesis [18]. In addition, Ad vectors have
been used to deliver PRRSV-targeted shRNAs in vitro
and in vivo [19]. However, PRRSV targets the cells of
monocyte/macrophage which are resistant to rAd trans-
duction due to the lack of high affinity Ad receptor [20].
More recently, it has been shown that the exosomes de-
rived from human and mouse cells can serve as an effi-
cient small RNA transfer vehicle [21]. Therefore, we
hypothesized that the co-delivery of Sn- and CD163-
targeted amiRNAs by rAds and exosomes could become
a novel strategy against PRRSV infection.
To test the above hypothesis, in this study we predicted
the candidate miRNAs targeting Sn or CD163 receptor
and validated them experimentally using a reporter assay.
Two rAds expressing the effective amiRNAs were gener-
ated for further study. Cell transduction assays showed
that the sequence-specific amiRNAs were expressed effi-
ciently in and secreted from rAd-transduced pig cells via
exosomes. In primary PAMs, the expression of two viral
receptors was inhibited significantly by transduction with
the amiRNA-expressing rAd and/or treatment with the
amiRNA-containing exosomes. Furthermore, PRRSV in-
fection of PAMs was inhibited significantly by transduc-
tion with the two amiRNA-expressing rAds and/or
treatment with the two amiRNA-containing exosomes.
These results supported the hypothesis that simultaneous
knock-down of Sn and CD163 receptors may become a
novel strategy against PRRSV infection. In addition, our
findings suggest that exosomes can also serve as an effi-
cient small RNA transfer vehicle for pig cells. To our
knowledge, this is the first study to explore an amiRNA
strategy against PRRSV infection by targeting the two viral
receptors.
Results
Prediction and validation of the miRNAs targeting Sn or
CD163 receptor
Computational prediction represents an effective strat-
egy for identification of the candidate siRNAs or miR-
NAs that can be validated experimentally. We analyzed
the first 1751-nt sequence of porcine Sn mRNA and the
1511-nt sequence of porcine CD163 mRNA for candi-
date miRNAs. Ten top-scoring miRNA sequences for
each target were reported and 18 of them (Table 1) were
selected for amiRNA vector construction (Figure 1A).
To facilitate the candidate miRNA validation, the first
1751-bp sequence of the Sn cDNA or the 1511-bp se-
quence of the CD163 cDNA was cloned in frame with
the green fluorescent protein (GFP) coding sequence in
Table 1 The oligonucleotides used for construction of amiRNA expression vectors in this study
Target miRNA Start Double-stranded oligonucleotide sequence (5′→3′)








































The candidate amiRNAs were predicted by following the instructions for the web-based Block-iTTM RNAi designer. The mature amiRNA and forward primer sequences
for the detection of amiRNAs in rAd-transduced cells are indicated as italics.
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Figure 1 Validation of Sn and CD163 receptor-targeted amiRNAs. (A) The schematic structure of amiRNA expression vector. PCMV, immediate
early promoter of cytomegalovirus; miR, miR-flanking sequences of mouse BIC non-coding mRNA; Pre-amiRNA, double? stranded oligonucleotide for
amiRNA; TK pA, TK gene poly(A) signal of human simplex herpes virus. (B) The schematic structure of the reporter vectors for amiRNA validation. PCMV,
immediate early promoter of cytomegalovirus; Sn/CD163, porcine Sn or CD163 receptor cDNA; GFP, green fluorescent protein coding sequence; SV40
pA, poly(A) signal of SV40 virus. (C or D) NIH 3 T3 cells were transfected with different amiRNA expression vector plus the reporter vector, and the
GFP-positive cell numbers were measured by flow cytometry 24 h after transfection. The know-down efficiency of each amiRNA was expressed as the
percent inhibition of total fluorescence in the cell culture co-transfected with the amiRNA expression vector and the reporter vector.
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or pCD163-GFP (Figure 1B). NIH 3 T3 cells were co-
transfected with each amiRNA expression vector and the
reporter vector, and the cell culture was assayed for GFP+
cells by flow cytometry. By using pSn-GFP-transfected cells
as the reference, transfection with each amiRSn expression
vector plus the reporter vector resulted in GFP+ cell num-
ber reductions ranging from 39.6% to 96.3% (Figure 1C).
Similarly, transfection with each amiRCD163 expression
vector plus the reporter vector led to GFP+ cell number re-
ductions ranging from 53.3% to 88.5% (Figure 1D). The
most effective amiRSn-2 and amiRCD163-2, as well as an
irrelevant amiRcon (Table 1), were selected for further
study.
rAd generation and cell transduction
We subcloned amiRSn-2, amiR163-2 or amiRcon expres-
sion cassette into Ad vector pShuttle-IRES-hrGFP, and
three rAds, namely rAd-amiRSn, rAd-amiR163 and rAd-
amiRcon, were generated by transfecting AAV-293 cells
with the rAd vectors (Figure 2A). Primary PAMs and PK-
15 cells were transduced with different doses of rAds, and
the cell cultures were analyzed for GFP+ cells since the
GFP reporter gene was included in the rAd vectors. Com-
pared to 100% transduction efficiency for PK-15 cells at
MOI 100 (Figure 2B), only 62% transduction efficiency
was achieved for PAMs at MOI 800 (Figure 2C), which
was not increased further by using higher MOI. The
different rAd transduction efficiencies for the two pig
cell types were confirmed by fluorescent microscopy
(Figure 2D). Therefore, the further experiments werecarried out at MOI 800 for PAM transduction and MOI
100 for PK-15 cell transduction.
The sequence-specific amiRNAs were expressed in and
secreted from the rAd-transduced cells
To investigate whether the amiRNAs were expressed in
rAd-transduced cells, primary PAMs or PK-15 cells were
transduced with rAd-amiRSn, rAd-amiRCD163 or rAd-
amiRcon, and the total RNA was extracted 48 h after
transduction. At the same time, the exosomes were puri-
fied from cell culture medium and the total RNA was
extracted for sequence-specific amiRNA detection. The
expected 80-nt amiRNAs were detected in all of the
three rAd-transduced cells (Figure 3A) and their exo-
somes (Figure 3B), but not in the mock-transduced cells
and their exosomes.
The rAd- and exosome-delivered amiRNA had an additive
effect against the target gene expression
The sufficient knock-down of Sn and CD163 receptors
is the precondition for the objective evaluation of anti-
PRRSV effects of the receptor-targeted amiRNAs. We
compared the knock-down efficiencies of the two viral
receptors using three different strategies: rAd transduc-
tion, exosome treatment and rAd transduction plus exo-
some treatment. First, primary PAMs were transduced
with rAd-amiRSn, rAd-amiR163 or rAd-amiRcon. After
incubation for 48 h, the total RNA was extracted for
mRNA detection by quantitative RT-PCR and the cell cul-
ture was analyzed for Sn+ or CD163+ cell number by flow
cytometry. Compared to that in rAd-amiRcon-transduced
Figure 2 rAd transduction efficiencies for pig cells. (A) The schematic structure of Ad vector for amiRNA expression. ITR, inverted terminal
repeat of adenovirus; PCMV, immediate early promoter of cytomegalovirus; miR, miR-flanking sequences of mouse BIC non-coding mRNA;
Pre-amiRNA, double? stranded oligonucleotide for amiRNA; IRES, internal ribosome entry sequence; GFP, green fluorescent protein coding
sequence; SV40 pA, poly(A) signal of SV40 virus. (B) PK-15 cells and (C) primary PAMs were transduced with different doses of rAd-amiRSn and the
GFP-positive cell numbers were measured by flow cytometry 48 h after transduction. (D) Primary PAMs and PK-15 cells were mock-transduced or
transduced with each rAd and analyzed by fluorescent microscopy (40?) 48 h after transduction.
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the rAd-amiRSn- or rAd-amiRCD163-transduced cells
was decreased by 0.51 or 0.54 fold (Figure 4A), while Sn+
and CD163+ cell numbers were decreased from 48.7% to
22.7% and from 49.9% to 27.6%, respectively (Figure 4B).
Next, primary PAMs were incubated with the exosomes
(0.5 mg protein/ml) derived from rAd-amiRSn- or rAd-
amiRCD163-transduced PK-15 cells. At 48 h after incuba-
tion, the total RNA was extracted for quantitative RT-PCR
and cell cultures were harvested for flow cytometry ana-
lysis as described. Compared to that in the two control
groups, Sn or CD163 mRNA expression in the amiRNA-
containing exosome-incubated cells was decreased by 0.41
or 0.46 fold (Figure 4A), while Sn+ and CD163+ cell
numbers were decreased to 33.4% and 36.5%, respectively
(Figure 4B). Finally, primary PAMs were transduced firstwith each rAd, incubated for 48 h with each amiRNA-
containing exosomes, the total RNA was extracted for
quantitative RT-PCR and the cell cultures were harvested
for flow cytometry analysis as described. Compared to that
in the two control groups, Sn or CD163 mRNA expression
was decreased by 0.73 or 0.73 fold (Figure 4A), while Sn+
and CD163+ cell numbers were decreased to 18.9% and
19.1%, respectively (Figure 4B).
Sn and CD163 receptor-targeted amiRNAs had an additive
effect against PRRSV infection
We used two different quantitative assays to evaluate
the additive anti-PRRSV effect between Sn and CD163
receptor-targeted amiRNAs: quantitative RT-PCR and viral
titration. For the quantitative RT-PCR, primary PAMs
were transduced with rAd-amiRcon, rAd-amiRSn and/or
Figure 3 Detection of amiRNA expression in the rAd-transduced cells and purified exosomes by RT-PCR. (A) Primary PAMs and PK-15 cells
were mock-transduced or transduced with each rAd, and the total RNA was extracted for sequence-specific amiRNA detection 48 h after transduction.
(B) The exosomes were purified from the cell culture medium of each rAd-transduced cells and the total RNA was extracted for sequence-specific
amiRNA detection 48 h after transduction.
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strain VR2332 (MOI 0.2) 48 h after transduction. At 24 h
post infection, the total RNA was extracted for quantita-
tive RT-PCR using PRRSV ORF7-specific primers (Table 2).
Compared to that (5.4 log10) in rAd-amiRcon-transduced
cells, the ORF7 copy number in rAd-amiRSn and/or rAd-
amiRCD163 transduced cells was decreased by 3.5, 2.3 or
2.6 log10 (Figure 5). Next, primary PAMs were incubated
with the exosomes derived from rAd-amiRSn- and/or
rAd-amiRCD163-transduced PK-15 cells, infected with
PRRSV and the total RNA was extracted for quantitative
RT-PCR as described. Compared to that (5.4 log10) in
the control group, the ORF7 copy number in amiRSn-
and/or amiRCD163-containing exosome-incubated cells
was decreased by 3.3, 2.0 or 2.2 log10 (Figure 5). Finally,
primary PAMs were transduced with different rAds, in-
cubated with different amiRNA-containing exosomes,
infected with PRRSV and total RNA was extracted for
RT-PCR as described. Compared to that (5.4 log10) in the
control group, the ORF7 copy number in double rAd-
transduced and double amiRNA-containing exosome-
incubated cells was decreased by 4.2 log10, while the
ORF7 copy number in single rAd-transduced and single
amiRNA-containing exosome-incubated cells was de-
creased by 3.3 or 3.6 log10 (Figure 5).For the viral titration assay, primary PAMs were trans-
duced with different rAds and infected with PRRSV strain
VR2332 as described. At different time points post infec-
tion, the cells were harvested for PRRSV titration on
MARC-145 cells. Compared to that (4.3 log10 TCID50) in
the mock- or rAd-amiRcon-transduced cells, the PRRSV
titer in rAd-amiRSn- and/or rAd-amiRCD163-transduced
cells was decreased by 1.5, 0.9 or 1.0 log10 at 24 h post in-
fection (Figure 6A). Next, primary PAMs were incubated
with amiRSn- and/or amiRCD163-containing exosomes,
infected with PRRSV and harvested for PRRSV titration as
described. Compared to that (4.3 or 4.2 log10 TCID50) in
the mock- or amiRcon-containing exosome-treated cells,
PRRSV titer in amiRSn- and/or amiRCD163-containing
exosome-incubated cells was decreased by 1.2, 0.6 or 1.0
log10 (Figure 6B). Then, primary PAMs were transduced
with different rAds, incubated with different amiRNA-
containing exosomes, infected with PRRSV and harvested
for PRRSV titration as described. Compared to that (4.3 or
4.4 log10 TCID50) in the two control groups, the PRRSV
titer in double rAd-transduced and double amiRNA-
containing exosome-incubated cells was decreased by 2.0
log10, while the viral titer in single rAd-transduced and
single amiRNA-containing exosome-incubated cells was
decreased by 1.1 log10 (Figure 6C). The similar additive
Figure 4 Knock-down of Sn or CD163 receptor by the rAd- and/or exosome-delivered amiRNA. (A) Primary PAMs were transduced with
each rAd and/or incubated with each amiRNA-containing exosomes derived from the rAd-transduced PK-15 cells. At 48 h after incubation, the
total RNA was extracted for Sn or CD163 mRNA detection by real-time quantitative RT-PCR. (B) The rAd-transduced and/or exosome-incubated
cells were stained with Sn- or CD163-specific antibody and analyzed by flow cytometry.
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least 96 h (Figure 6A,B or C). Finally, primary PAMs were
transduced with different rAds, incubated with different
amiRNA-containing exosomes and infected with PRRSV
strain JX-A1, CH-1R or VR2332 as described. At 72 h post
infection, the infected cells were harvested for PRRSV ti-
tration. Compared to that (4.9-6.2 log10 TCID50) in the
two control groups, the PRRSV titers in three viral strain-
infected cells were decreased by 2.7, 2.1 and 2.6 log10, re-
spectively (Figure 6D).
Discussion
As a natural antiviral mechanism, RNAi has become a
feasible strategy against a variety of viral infections [13],
but its in vivo use is limited by the low efficiency ofsmall RNA delivery. Such drawbacks can be alleviated by
using viral vectors for small RNA delivery. Among the
viral vectors available, Ads have several advantages and
thus have been used extensively as the gene transfer vec-
tors for gene therapy and vaccine development [18]. Fur-
thermore, Ads have been shown to an efficient shRNA
delivery vehicle for pig cells [19]. Therefore, in this study
we used rAd vectors as the amiRNA delivery vehicle.
Cell transduction experiments showed that the human
Ad5-based vectors could not only transduce pig cells
(Figure 2), but also express the encoded amiRNAs effi-
ciently (Figure 3). Unlike pig kidney PK-15 cells, how-
ever, primary PAMs were resistant to rAd transduction
and only a maximal transduction efficiency of about 60%
was achievable by using very high doses (MOI ≥ 800) of
Table 2 The primers used for PCR or real-time quantitative













PRRSV For CCAGCCAGTCAATCARCT 208
ORF7 Rev GCGAATCAGGCGCACWGTATG
GAPDH For ACACTCACTCTTCTACCTTTG 90
Rev CAAATTCATTGTCGTACCAG
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lack of high affinity Ad receptor on primary PAMs,
which has been reported for the primary macrophages
in other species [20].
As a natural mechanism in animal cells, the exosomes
derived from human and mouse cells can serve as an ef-
ficient vehicle for small RNA transfer [21]. In the light
of resistance of PAMs to rAd transduction, this war-
ranted us to explore the feasibility of pig cell-derived
exosomes as a small RNA delivery vehicle, which has
not been reported in livestock such as pigs. Our RT-PCR
assay showed that the sequence-specific amiRNAs were
easily detected in the exosomes purified from the cell
culture medium of rAd-transduced pig cells (Figure 3B),
indicating that the viral vector-encoded amiRNAs wereFigure 5 Detection of PRRSV ORF7 copy numbers in rAd-transduced a
with single or double rAds and/or incubated for 48 h with single or double
strain VR-2332 and the total RNA was extracted 24 h post infection for ORFsecreted from the pig cells via exosomes. Furthermore,
the sequence-specific amiRNAs were detected in the
exosome-incubated PAMs (data not shown) and showed
significant inhibitory effects against PRRSV infection
(Figures 5 and 6). These results suggested that exosomes
could also serve as an efficient small RNA transfer ve-
hicle for pig cells.
PRRSV uses at least three receptors to enter PAMs,
among which Sn and CD163 play essential but different
roles [10]. It has been shown that PRRSV infection of
PAMs can be blocked partially by Sn- or CD163-specific
antibody, or completely by a combination of two anti-
bodies [11]. Our previous study has also shown that the
soluble Sn and CD163 receptors have an additive effect
against PRRSV infection [12]. These indicate that the
simultaneous knock-down of two viral receptors is re-
quired to achieve a significant antiviral effect. In the
light of resistance of PAMs to rAd transduction, we
compared Sn and CD163 receptor knock-down efficien-
cies of three different strategies: rAd transduction, exo-
some treatment and rAd transduction plus exosome
treatment. Both quantitative RT-PCR and flow cytome-
try analyses showed that, compared to the lower
knocking-down efficiency of Sn or CD163 receptor by
rAd transduction or exosome treatment, the rAd trans-
duction plus exosome treatment resulted in significantly
more knock-down of the two viral receptors at both
mRNA and protein levels (Figure 4). These results sug-
gested that exosomes could assist rAds to deliver small
RNAs into pig cells, which was particularly important
for the delivery of amiRNAs into PAMs that were resist-
ant to rAd transduction.
Similarly, we used the three different strategies to in-
vestigate the additive anti-PRRSV effect between Sn andnd/or exosome-incubated PAMs. Primary PAMs were transduced
amiRNA-containing exosomes. The cells were infected with PRRSV
7 copy number detection by real time quantitative RT-PCR.
Figure 6 Titration of PRRSV titers in rAd-transduced and/or exosome-incubated PAMs. (A) Primary PAMs were transduced with different rAds and
infected with PRRSV strain VR2332 48 h after transduction. At different time points after infection, the cells were harvested for PRRSV titration on MARC-145
cells. (B) Primary PAMs were incubated for 48 h with different amiRNA-containing exosomes and then infected with PRRSV strain VR2332 before PRRSV
infection and titration. (C) Primary PAMs were transduced with different rAds and then incubated for 48 h with different amiRNA-containing exosomes
before PRRSV infection and titration. (D) Primary PAMs were transduced with different rAds and then incubated for 48 h with different amiRNA-containing
exosomes. The cells were infected with three different PRRSV strains and harvested for PRRSV titration 72 h after infection.
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PCR showed that the simultaneous knock-down of two
viral receptors resulted in more reductions in PRRSV
ORF7 copy number than the single receptor knock-
down (Figure 5). In addition, much more reduction in
the ORF7 copy number was achieved by using rAd
transduction plus exosome treatment (Figure 5). The
similar results were obtained from viral titration assays
(Figure 6,B and C). The additive anti-PRRSV effect be-
tween the two viral receptor-targeted amiRNAs was rela-
tively long-lasting (96 h) and effective against all three
different viral strains tested (Figure 6D). However, the
complete inhibition was not achieved by using three dif-
ferent strategies and very high rAd doses (MOI ≥ 800)for cell transduction. This could be explained by the fol-
lowing reasons: first, Sn and/or CD163 receptor-targeted
amiRNAs delivered by three different strategies were
insufficient for the complete know-down of two viral
receptors (Figure 4) due to the inherent incomplete
knock-down of RNAi strategy [22], and/or the resistance
of primary PAMs to rAd transduction [20]. Second, the
turnover of Sn and/or CD163 receptor was longer than
that we tested (48 h) and thus the certain amounts
of pre-expressed receptors were present on the rAd-
transduced and/or exosome-incubated PAMs. Finally,
there were alternative cellular factor (s) may be involved
in PRRSV infection of primary PAMs. Among these,
CD151 may be an important one since it plays an
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and is expressed on primary PAMs [23,24]. These war-
rant us to refine the amiRNA strategy by targeting more
cellular factors and/or using more efficient amiRNA
transfer vectors such as recombinant lentiviruses.
Both Sn and CD163 receptors are macrophage-
restricted cell surface molecules that are conserved across
mammals. Among these, Sn receptor is a member of the
sialic acid-binding IgG-like lectin family of proteins which
contributes to sialylated pathogen uptake, antigen pre-
sentation and lymphocyte proliferation [25], while CD163
receptor is a critical for the efficient extracellular he-
moglobin clearance during hemolysis [26]. Therefore,
whether the knock-down of two receptors could influence
the viability or compromise the cell functions of PAMs
should be considered. In the light of the fact that expres-
sion of the two receptors are regulated by several factors
such as glucocorticoids and IL-10, and that the expression
levels vary significantly under different conditions [15,26],
we speculated that the two genes were not vital for the cell
viability. This speculation was supported by an additional
fact that the viability of PAM cell lines is not compro-
mised by the loss of Sn and/or CD163 expression [27]. In
any case, more studies are certainly needed to address the
safety of our amiRNA strategy before its in vivo use.
In summary, in this study we generated two rAds ex-
pressing Sn or CD163 receptor-targeted amiRNA and
investigated their anti-PRRSV effect using different strat-
egies. The Ad vectors could not only transduce different
pig cells, but also express the vector-encoded amiRNAs.
The vector-expressed amiRNAs were secreted from
rAd-transduced cells via exosomes not only, but taken
up by other pig cells as well. A significant additive anti-
PRRSV effect between the two amiRNAs was demon-
strated by transduction of PAMs with the two rAds or
by incubation with the two amiRNA-containing exo-
somes, which was enhanced further by co-transduction
with the two rAds plus co-incubation with the two
amiRNA-containing exosomes. According to our know-
ledge, this is the first study to explore an amiRNA strat-
egy against PRRSV infection by targeting the two viral
receptors. In addition, we provided new evidence that
the exosomes could also serve as an efficient small RNA
deliver vehicle for pig cells. Although the complete anti-
PRRSV effect has not yet been demonstrated, this study
may facilitate further works on development of more ef-
ficient strategies against PRRS.
Conclusion
This study demonstrated that Sn and CD163 receptor-
targeted amiRNAs had an additive anti-PRRSV effect
against different viral strains. In addition, we provided
new evidence that the exosomes could serve as an efficient
small RNA deliver vehicle for pig cells.Methods
Cells, viruses and reagents
Mouse fibroblast cell line L-929 (ATCC CCL-1) was grown
in Dulbecco? s Modified Eagle? s Medium (DMEM)/Nutrient
Mixture F-12 (Gibco, USA) supplemented with 10% fetal
bovine serum (FBS) and 1% non-essential amino acids. Pig
kidney cell line PK-15 (ATCC CCL-33), mouse embryo
fibroblast cell line NIH 3 T3 (ATCC CRL-1658), AAV-293
cells (Stratagene, USA) and African green monkey kidney
cell line MARC-145 cells (ATCC CRL-12231) were grown
in DMEM supplemented with 10% FBS and 1% non-
essential amino acids. Primary PAMs were prepared from
6-week-old Lancrace pigs as described previously [7] and
grown in DMEM/F-12 supplemented with 10% FBS, 1%
non-essential amino acids and 20% L-929-conditioned
medium. PRRSV strain VR-2332 (ATCC VR2332) is a
prototype strain of North American genotype [28]. PRRSV
strain CH-1R is an attenuated vaccine strain derived from
the traditional Chinese strain CH-1a [29]. PRRSV strain
JX-A1 is a highly pathogenic Chinese strain [30]. The three
PRRSV strains were propagated and titrated on MARC-
145 cells.
miRNA prediction and double-strand oligonucleotide
prepration
The first 1751-nt sequence of porcine Sn mRNA (Gen-
Bank: AF505985) and the 1511-nt sequence of porcine
CD163 mRNA (GenBank: NM_213976) were predicted
using the web-based BLOCK-iT ? RNAi designer (Invi-
trogen, USA). Among 10 top-scoring sequences reported
for each target, 18 of them were selected for miR RNAi
design according to their higher knock-down probabil-
ities (star rankings). The top- and bottom-strand oligo-
nucleotides (Table 1) were synthesized, each pair of
them (5 μl, 200 μM) was denatured at 94?C for 5 min
and slowly annealed at room temperature to form
double-strand oligonucleotide.
Vector construction
For construction of the amiRNA expression vectors, each
double-strand oligonucleotide was cloned at the BbsI site
of amiRNA expression vector pcDNA-miR [31], in which
the amiRNA expression cassette consists of the 5′- and 3′-
miR flanking sequences of mouse BIC non-coding mRNA,
followed by the poly(A) signal of human herpesvirus
TK gene (Figure 1A). The recombinant vectors, namely
pcDNA-miRSn (1? 9), pcDNA-miRCD163 (1? 9) or control
pcDNA-miRcon, were used for amiRNA validation.
For construction of the reporter vectors, the cellular
RNA was extracted from primary PAMs using RNAiso
Plus (KaTaRa, Dalian, China) according to the manu-
facturer ? s instructions. The reverse transcription (20 μl)
was performed using RevertAid ? Reverse Transcriptase
(Fermentas, USA) by following the manufacturer ? s
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product and LA Taq DNA Polymerase (KaTaRa, Dalian,
China) according to the manufacturer? s manual. The first
1751-bp Sn cDNA segment was amplified using primers
Sn For1 and Sn Rev1 (Table 2). The PCR was carried out
at 94?C for 5 min; 30 cycles of 94?C for 45 sec, 60?C for
45 sec and 72?C for 2 min; and a final extension at 72?C
for 10 min. The first 1511-bp CD163 cDNA segment was
amplified using primers CD163 For1 and CD163 Rev1
(Table 2). The PCR was carried out at 94?C for 5 min;
30 cycles of 94?C for 45 sec, 50?C for 45 sec and 72?C for
1.5 min; and a final extension at 72?C for 10 min. Each
PCR product was cloned into pMD18-T vector for se-
quencing and then at the XhoI/BamHI site of pEGP-N1
vector (Invitrogen, USA) to produce reporter vector pSn-
EGFP or pCD163-EGFP (Figure 1B). The expression of
two GFP fusions was checked by transfection of NIH 3 T3
cells and fluorescent microscopy.
For construction of the rAd vectors, the amiRSn-2,
amiRCD163-2 or amiRcon expression cassette was excised
from the amiRNA expression vector by restriction diges-
tion with AatII and PvuI, and cloned into pShuttle-IRES-
hrGFP (Stratagene, USA) vector after linerization with the
same enzymes. The pShuttle-IRES-hrGFP vector is ren-
dered replication defective by deletion of the E1 and E3
genes [32], and by inclusion of humanized Renilla reni-
formis GFP (hrGFP) sequence after the internal ribo-
some entry site (IRES) for follow-up purpose. The
resultant rAd vector was called pShuttle-amiRSn-IRES-
hrGFP, pShuttle-amiRCD163-IRES-hrGFP or pShuttle-
amiRcon-IRES-hrGFP (Figure 2A).
Candidate amiRNA validation
NIH 3 T3 cells were seeded in triplicates at 5 ? 10 5/well
on 24-well plates and grown to 70% confluent growth.
The cells were transfected with pcDNA-amiRSn (1? 9),
pcDNA-amiRCD163 (1? 9) or pcDNA-amiRcon (2 μg/
well) plus pSn-EGFP or pCD163-EGFP (0.4 μg/well). The
transfection was performed using Lipofectamine? 2000
(Invitrogen, USA) according to the manufacturer ? s man-
ual. At 24 h after transfection, the cells were trypsinized,
washed three times with PBS, diluted to 106 cells/ml and
analyzed (104 cells) for total fluorescence and cell numbers
on BD FACSAia III (BD, USA). The effectiveness of each
amiRNA was expressed as the percent inhibition of Sn-
GFP or CD163-GFP fusion expression using pSn-GFP- or
pCD163-GFP-transfected as the reference.
rAd preparation and cell transduction
The three rAds, namely rAd-amiRSn, rAd-amiRCD163
and rAd-amiRcon, were generated by transfecting AAV-
293 cells (Stratagene, USA) with the rAd vectors according
to the instruction manual for AdEasy? Adenoviral Vector
System (Agilent Technologies, USA). The rAds wereamplified on AAV-293 cells, purified using ViraBind?
Adenovirus Miniprep Kit (CELL BIOLABS, USA) by fol-
lowing the manufacturer? s protocol, and titrated on AAV-
293 cells as fluorescent formation units (FFU)/ml. For
transduction of PK-15 cells, the cells were seeded in tripli-
cates at 5 ? 10 4 cells/well on 24-well plates, and grown to
80% confluent growth. After two time wash with PBS, the
cells were transduced (37?C for 2 h) with different doses
(MOI) of rAds. The transduction of primary PAMs was
carried out as previously described [33]. Briefly, the cells
were cultured for 7 days in the growth medium condi-
tioned with 20% of L-929 cell culture medium. The cells
were trypsinized, diluted to 105cells/ml with the same
medium, mixed with different doses of rAds and centri-
fuged at 2000 ? g for 1 h at 37?C. After wash again with
PBS, the cells were grown for additional 48 h in the fresh
medium and assayed for GFP-positive cells on BD FAC-
SAia III or by fluorescent microscopy.
Exosome purification
Exosome purification was performed as previously de-
scribed [34]. Briefly, primary PAMs and PK-15 cells were
seeded in T75 flasks and grown to 70% confluent growth
in the medium supplemented with 10% exosome-
depleted FBS. The cells were transduced with each rAd
(MOI 800 for primary PAMs or 100 for PK-15 cells) and
incubated for additional 48 h. The cell medium was col-
lected and centrifuged at 4?C, 300 g for 10 min, 1000 g
for 30 min, 10,000 g for 45 min to remove the cell deb-
ris. After filtration through a 0.22-μm filter membrane,
the exosomes were precipitated by centrifugation at
120,000 g for 70 min and suspend in PBS for immediate
use or stored at ? 80?C for later use.
Poly(A)-tailed RT-PCR
The poly(A)-tailed RT-PCR for amiRNA detection was
performed using One Step Prime Script miRNA cDNA
Synthesis Kit (KaTaRa, Dalian China) by following the
manufacturer? s protocol. Briefly, the total RNA was ex-
tracted from rAd-transduced cells or purified exosomes
for cDNA synthesis. Each amiRNA cDNA was amplified
using the sequence-specific forward primer (Table 1) and
the general reverse primer in the cDNA synthesis kit. The
PCR was carried out at 95?C for 30 sec, 35 cycles of 95?C
for 10 sec, 58?C for 30 sec, 72?C for 10 sec, and a final ex-
tension at 72?C for 5 min. The PCR products (8 μl) were
analyzed by electrophoresis on a 3% agarose gel.
Quantitative RT-PCR
The real-time quantitative RT-PCR for Sn and CD163 re-
ceptor mRNA detection was performed as described previ-
ously [35]. Briefly, primary PAMs were transduced in
triplicates with each rAd and incubated in the medium with
or without the exosomes (0.5 mg protein/ml) purified from
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the total RNA was extracted for reverse transcription using
RevertAidTM Reverse Transcriptase (Fermentas, USA). The
Sn and CD163 receptor mRNA expression was analyzed by
SYBR green-based real-time quantitative PCR using Roche
LightCycler Nano system. The mRNA copy number was
normalized by comparing to house-keeping GAPDH copy
number. The primer sequences are listed in Table 2.
The real-time quantitative RT-PCR for PRRSV ORF7
copy number detection was performed as previously de-
scribed [36]. Briefly, primary PAMs were transduced in
triplicates with different rAds and/or incubated in the
growth medium with or without the exosomes derived
from rAd-transduced cells as described. At 48 h after in-
cubation, the cells were infected with PRRSV (MOI 0.2),
incubated for additional 24 h and total RNA was extracted
for reverse transcription and real-time quantitative PCR as
described. The standard curve was generated by compar-
ing to PRRSV ORF7-containing plasmid [36]. The primer
sequences are listed in Table 2.
Flow cytometry analysis for detection of Sn and CD163
receptor knock-down
The flow cytometry for detection of Sn and CD163 recep-
tor knock-down was performed as previously described
[37]. Briefly, primary PAMs were transduced in triplicates
with different rAds and/or incubated for 48 h with or
without the exosomes derived from rAd-transduced cells.
The cells were stained with Sn- or CD163-specific anti-
body and analyzed by flow cytometry as described.
PRRSV infection and titration
Primary PAMs were seeded at 2 ? 10 5/ml on 24-well
plates and grown overnight in the medium supple-
mented with 10% exosome-depleted FBS. The cells were
mock-transduced in triplicates or transduced with differ-
ent rAds and/or incubated for 48 h with or without the
exosomes (0.5 mg protein/ml) purified from different
rAd-transduced PK-15 cells. The cells were infected with
PRRSV strain VR-2332, CH-1R or JX-A1 (MOI 0.2) and
harvested at different time points for PRRSV titration on
MARC-145 cells as previously described [38].
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